Chemoprevention for Breast Cancer

Sandhya Pruthi, Ruth E. Heisey, Therese B. Bevers

Research output: Contribution to journalArticle

19 Citations (Scopus)

Abstract

Background: Many women at increased risk for breast cancer could benefit from preventive therapy. Preventive therapy options for breast cancer risk reduction have expanded in the last few years to include both selective receptor modulators (tamoxifen and raloxifene) and aromatase inhibitors (anastrozole and exemestane). Methods: Risk factors that place women at high risk for breast cancer, as well as risk calculation models appropriate for the selection of candidates for preventive therapy, are presented, followed by a review of current guidelines for chemoprevention and results of chemoprevention trials. Results: The modified Gail model or Breast Cancer Risk Assessment Tool is the most widely utilized risk assessment calculator to determine eligibility for chemoprevention. Women most likely to benefit from preventive therapy include those at high risk under the age of 50 years and those with atypical hyperplasia. Physician and patient barriers limit widespread acceptance and adherence to preventive therapy. Conclusions: Published guidelines on chemoprevention for breast cancer have been updated to increase awareness and encourage discussion between patients and their physicians regarding evidence-based studies evaluating the benefits of preventive options for women at increased risk for breast cancer. However, even with increasing awareness and established benefits of preventive therapy, the uptake of chemoprevention has been low, with both physician and patient barriers identified. It is prudent that these barriers be overcome to enable high-risk women with a favorable risk-to-benefit ratio to be offered chemoprevention to reduce their likelihood of developing hormone receptor-positive breast cancer.

Original languageEnglish (US)
Pages (from-to)3230-3235
Number of pages6
JournalAnnals of Surgical Oncology
Volume22
Issue number10
DOIs
StatePublished - Jul 23 2015

Fingerprint

Chemoprevention
Breast Neoplasms
exemestane
Physicians
Therapeutics
Guidelines
Aromatase Inhibitors
Tamoxifen
Risk Reduction Behavior
Hyperplasia
Hormones

ASJC Scopus subject areas

  • Surgery
  • Oncology

Cite this

Chemoprevention for Breast Cancer. / Pruthi, Sandhya; Heisey, Ruth E.; Bevers, Therese B.

In: Annals of Surgical Oncology, Vol. 22, No. 10, 23.07.2015, p. 3230-3235.

Research output: Contribution to journalArticle

Pruthi, Sandhya ; Heisey, Ruth E. ; Bevers, Therese B. / Chemoprevention for Breast Cancer. In: Annals of Surgical Oncology. 2015 ; Vol. 22, No. 10. pp. 3230-3235.
@article{4b79c4fa9c5c4142b8f7f0b9bebdee68,
title = "Chemoprevention for Breast Cancer",
abstract = "Background: Many women at increased risk for breast cancer could benefit from preventive therapy. Preventive therapy options for breast cancer risk reduction have expanded in the last few years to include both selective receptor modulators (tamoxifen and raloxifene) and aromatase inhibitors (anastrozole and exemestane). Methods: Risk factors that place women at high risk for breast cancer, as well as risk calculation models appropriate for the selection of candidates for preventive therapy, are presented, followed by a review of current guidelines for chemoprevention and results of chemoprevention trials. Results: The modified Gail model or Breast Cancer Risk Assessment Tool is the most widely utilized risk assessment calculator to determine eligibility for chemoprevention. Women most likely to benefit from preventive therapy include those at high risk under the age of 50 years and those with atypical hyperplasia. Physician and patient barriers limit widespread acceptance and adherence to preventive therapy. Conclusions: Published guidelines on chemoprevention for breast cancer have been updated to increase awareness and encourage discussion between patients and their physicians regarding evidence-based studies evaluating the benefits of preventive options for women at increased risk for breast cancer. However, even with increasing awareness and established benefits of preventive therapy, the uptake of chemoprevention has been low, with both physician and patient barriers identified. It is prudent that these barriers be overcome to enable high-risk women with a favorable risk-to-benefit ratio to be offered chemoprevention to reduce their likelihood of developing hormone receptor-positive breast cancer.",
author = "Sandhya Pruthi and Heisey, {Ruth E.} and Bevers, {Therese B.}",
year = "2015",
month = "7",
day = "23",
doi = "10.1245/s10434-015-4715-9",
language = "English (US)",
volume = "22",
pages = "3230--3235",
journal = "Annals of Surgical Oncology",
issn = "1068-9265",
publisher = "Springer New York",
number = "10",

}

TY - JOUR

T1 - Chemoprevention for Breast Cancer

AU - Pruthi, Sandhya

AU - Heisey, Ruth E.

AU - Bevers, Therese B.

PY - 2015/7/23

Y1 - 2015/7/23

N2 - Background: Many women at increased risk for breast cancer could benefit from preventive therapy. Preventive therapy options for breast cancer risk reduction have expanded in the last few years to include both selective receptor modulators (tamoxifen and raloxifene) and aromatase inhibitors (anastrozole and exemestane). Methods: Risk factors that place women at high risk for breast cancer, as well as risk calculation models appropriate for the selection of candidates for preventive therapy, are presented, followed by a review of current guidelines for chemoprevention and results of chemoprevention trials. Results: The modified Gail model or Breast Cancer Risk Assessment Tool is the most widely utilized risk assessment calculator to determine eligibility for chemoprevention. Women most likely to benefit from preventive therapy include those at high risk under the age of 50 years and those with atypical hyperplasia. Physician and patient barriers limit widespread acceptance and adherence to preventive therapy. Conclusions: Published guidelines on chemoprevention for breast cancer have been updated to increase awareness and encourage discussion between patients and their physicians regarding evidence-based studies evaluating the benefits of preventive options for women at increased risk for breast cancer. However, even with increasing awareness and established benefits of preventive therapy, the uptake of chemoprevention has been low, with both physician and patient barriers identified. It is prudent that these barriers be overcome to enable high-risk women with a favorable risk-to-benefit ratio to be offered chemoprevention to reduce their likelihood of developing hormone receptor-positive breast cancer.

AB - Background: Many women at increased risk for breast cancer could benefit from preventive therapy. Preventive therapy options for breast cancer risk reduction have expanded in the last few years to include both selective receptor modulators (tamoxifen and raloxifene) and aromatase inhibitors (anastrozole and exemestane). Methods: Risk factors that place women at high risk for breast cancer, as well as risk calculation models appropriate for the selection of candidates for preventive therapy, are presented, followed by a review of current guidelines for chemoprevention and results of chemoprevention trials. Results: The modified Gail model or Breast Cancer Risk Assessment Tool is the most widely utilized risk assessment calculator to determine eligibility for chemoprevention. Women most likely to benefit from preventive therapy include those at high risk under the age of 50 years and those with atypical hyperplasia. Physician and patient barriers limit widespread acceptance and adherence to preventive therapy. Conclusions: Published guidelines on chemoprevention for breast cancer have been updated to increase awareness and encourage discussion between patients and their physicians regarding evidence-based studies evaluating the benefits of preventive options for women at increased risk for breast cancer. However, even with increasing awareness and established benefits of preventive therapy, the uptake of chemoprevention has been low, with both physician and patient barriers identified. It is prudent that these barriers be overcome to enable high-risk women with a favorable risk-to-benefit ratio to be offered chemoprevention to reduce their likelihood of developing hormone receptor-positive breast cancer.

UR - http://www.scopus.com/inward/record.url?scp=84940449568&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84940449568&partnerID=8YFLogxK

U2 - 10.1245/s10434-015-4715-9

DO - 10.1245/s10434-015-4715-9

M3 - Article

VL - 22

SP - 3230

EP - 3235

JO - Annals of Surgical Oncology

JF - Annals of Surgical Oncology

SN - 1068-9265

IS - 10

ER -